ArticleInfection and drug resistance2023
Characterization of ST11 and ST15 Carbapenem-Resistant Hypervirulent
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- HypervirulentOpen forum infectious diseases · 2026Article
- Molecular Insights Into Hypervirulent Klebsiella pneumoniae: Identification and Correlation of Virulence Determinant.MicrobiologyOpen · 2026Article
- Genomic surveillance reveals long-term endemicity and outbreak potential ofMicrobial genomics · 2026Article
- Clinical characteristics and molecular evolution of ST11-KL64 carbapenem-resistant hypervirulentMicrobiology spectrum · 2026Article
- Microbiological characterization and clinical outcomes of carbapenem-resistant enterobacterales infections in a paediatric hospital in Mexico.BMC infectious diseases · 2026Observational
- Emergence and clinical challenges of ST11-K64 carbapenem-resistant Klebsiella pneumoniae: molecular insights and implications for antimicrobial resistance and virulence in Southwest China.BMC infectious diseases · 2025Article
- Detection of Hypervirulence Genes and Drug Resistance inScientifica · 2025Article
- Extended-Spectrum β-Lactamase-ProducingInfection and drug resistance · 2025Article
- Molecular epidemiology of carbapenem-resistantFrontiers in microbiology · 2025Article
- Emergence of a novel sequence type carbapenem-resistant hypervirulentMicrobiology spectrum · 2024Article
- Virulence Factors and Carbapenem-Resistance Mechanisms in HypervirulentInfection and drug resistance · 2024Review
- Multidrug-resistant ST11-KL64 hypervirulentFrontiers in pediatrics · 2024Article
- Study of the Epidemiological and Mechanistic Differences Between Carbapenem-ResistantInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of carbapenem-resistant hypervirulent Methods: Data analysis of ICU patients suffering from ventilator-associated pneumonia (VAP) because of hv-CRKP infection, admitted at the Chinese Teaching Hospital between March 2019 and September 2021 was performed. Patients' antibiotic-resistance genes, virulence-associated genes, and capsular serotypes of these isolates were detected. Homology analysis of the strains was performed by MLST and PFGE. Six different strains were tested for their virulence traits using the serum killing test and the Results: Clinical data of 19 hv-CRKP-VAP patients were collected and their hv-CRKP were isolated, including 10 of ST11-KL64, 4 of ST15-KL112, 2 of ST11-KL47, 1 of ST15-KL19, 1 of ST17-KL140, and 1 of ST48-KL62. Four ST15 and 8 ST11 isolates revealed high homology, respectively. Most strains carried the carbapenemase gene Conclusion: This study highlights the dominant strain and molecular epidemiology of hv-CRKP in a hospital in China. We should pay more attention to the effect of hv-CRKP on VAP, strengthen monitoring and control transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.